Table 1 Patient and treatment characteristics for patients with unresectable bulky tumors treated with SBRT partial tumor irradiation targeting the hypoxic tumor segment (SBRT-PATHY)
Characteristic | No. (%) |
|---|---|
Sex | |
 Male | 17 (74) |
 Female | 6 (26) |
 Median age at SBRT-PATHY | 74 years, range: 41–86 |
Primary tumor site | |
 Lung | 16 (69.6) |
 Kidney | 3 (13.1) |
 Skin | 2 (8.7) |
 Prostate | 1 (4.3) |
 Unknown | 1 (4.3) |
Histology | |
 Adenocarcinoma | 5 (21.7) |
 Squamous | 13 (56.6) |
 Melanoma | 1 (4.3) |
 Renal cell carcinoma | 3 (13.1) |
 Unknown | 1 (4.3) |
Treated site | |
 Lymph node metastases: Neck levels IIA right and IV left Retroperitoneal Mediastinum | 5 (21.7) |
 Lung primary: Central: ULL, LLL, URL, Mediastinum Peripheral: LRL, URL, ULL, LLL | 14 (60.9) |
 Lung metastases: Peripheral: LRL, ULL | 3 (13.1) |
 Adrenal gland (left) | 1 (4.3) |
 Oligo-metastatic patients: | 14 (60.9) |
 1 metastasis | 3 (21.4) |
 > 1 ≤ 3 metastases | 8 (57.1) |
 > 3 ≤ 5 metastases | 3 (21.4) |
 Metastatic site(s) | Lung, Neck, Mediastinum, Soft Tissue, Retroperitoneal, Adrenal, Bone, Liver |
 Metastases in the same organ as treated bulky | 2 (14.3) |
 Metastases in the different organ(s) | 7 (50) |
 Both (in the same and in the different organs) | 5 (35.7) |
 Systemic therapy | 7 (30.4) |
 Chemotherapy | 4 (17) |
 Immunotherapy | 2 (8.7) |
 Hormonal (androgen deprivation therapy) | 1 (4.3) |
 GTV volume mean/range (cm3) | 179.8/30–499 |
 GTV diameter mean/range (cm) | 9.1/6–17 |
 BTV volume mean/range (cm3) | 57.1/5–137 |
 SUVmax mean/range for GTV | 23/7–85 |
 SUVmax mean/range for BTV | 3/1–3 |
Prescription dose | |
 10Gy × 1 to 70% isodose-line | 15 (65.2) |
 12Gy × 1 to 70% isodose-line | 4 (17.4) |
 10Gy × 3 to 70% isodose-line | 4 (17.4) |